Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia

Affiliations

• ¹ Hematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford.
• ² New York-Presbyterian Columbia University Medical Center, New York, NY.
• ³ Memorial Sloan Kettering Cancer Center, New York, NY.
• ⁴ Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA.
• ⁵ Dept. of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation.
• ⁶ Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY.
• ⁷ Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
• ⁸ Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC.
• ⁹ Weill Cornell Medicine School of Medicine, Long Island City, NY.
• ¹⁰ Div. of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
• ¹¹ Div of Hematology and Oncology,Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
• ¹² Aptitude Health, Atlanta, GA.
• ¹³ Novant Health, Charlotte, NC.
• ¹⁴ John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ.
• ¹⁵ Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC.
• ¹⁶ Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.
• ¹⁷ Department of Medicine, Cancer Center, Tufts Medical Center, Boston, MA.
• ¹⁸ Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA.
• ¹⁹ Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, NC.
• ²⁰ Dept of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation.
• ²¹ Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford.
• ²² Department of Haematology, Addenbrookes, Cambridge.
• ²³ Nottingham University Hospitals NHS Trust, Nottingham.